Moderna (MRNA) Other Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has 10 years of Other Accumulated Expenses data on file, last reported at $220.0 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 12.7% year-over-year to $220.0 million in Q1 2026; TTM through Mar 2026 was $220.0 million, a 12.7% decrease from a year earlier, with the FY2025 full-year figure at $185.0 million, down 16.29% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $220.0 million, up from $185.0 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for MRNA reached as high as $553.0 million in Q3 2022 and fell as low as $42.0 million in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $218.3 million across 5 years, with a median of $220.0 million in 2026.
• Across the five-year window, Other Accumulated Expenses slumped 82.2% in 2024 and surged 357.14% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $249.0 million in 2022, then slumped by 48.19% to $129.0 million in 2023, then jumped by 71.32% to $221.0 million in 2024, then dropped by 16.29% to $185.0 million in 2025, then grew by 18.92% to $220.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $220.0 million in Q1 2026, $185.0 million in Q4 2025, and $73.0 million in Q3 2025.